Zhengye Biotechnology Holding (ZYBT) Cash & Equivalents (2022 - 2025)

Zhengye Biotechnology Holding (ZYBT) has reported Cash & Equivalents for 4 consecutive years, with $7.1 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Cash & Equivalents rose 174.0% year-over-year to $7.1 million in Q4 2025; TTM through Dec 2025 was $7.1 million, a 174.0% increase from a year earlier, with the FY2025 full-year figure at $7.2 million, up 170.46% from the prior year.
• Cash & Equivalents was $7.1 million for Q4 2025 at Zhengye Biotechnology Holding, up from $6.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $7.1 million in Q4 2025 and troughed at $1.4 million in Q4 2022.
• A 4-year average of $4.2 million and a median of $3.8 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 175.54% in 2023 and tumbled 31.41% in 2024, its largest moves.
• Over 4 years, Cash & Equivalents stood at $1.4 million in 2022, then soared by 175.54% to $3.8 million in 2023, then sank by 31.41% to $2.6 million in 2024, then surged by 174.0% to $7.1 million in 2025.
• The last three Cash & Equivalents figures came in at $7.1 million (Q4 2025), $6.4 million (Q2 2025), and $2.6 million (Q4 2024), per Business Quant data.